131 related articles for article (PubMed ID: 38308608)
1. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.
Dinetz E; Lee E
Altern Ther Health Med; 2024 Jan; 30(1):6-12. PubMed ID: 38308608
[TBL] [Abstract][Full Text] [Related]
2. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
Mao L
Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535
[TBL] [Abstract][Full Text] [Related]
3. Deciphering cellular biological processes to clinical application: a new perspective for Tα1 treatment targeting multiple diseases.
Matteucci C; Argaw-Denboba A; Balestrieri E; Giovinazzo A; Miele M; D'Agostini C; Pica F; Grelli S; Paci M; Mastino A; Sinibaldi Vallebona P; Garaci E; Tomino C
Expert Opin Biol Ther; 2018 Jul; 18(sup1):23-31. PubMed ID: 30063863
[TBL] [Abstract][Full Text] [Related]
4. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.
Shehadeh F; Benitez G; Mylona EK; Tran QL; Tsikala-Vafea M; Atalla E; Kaczynski M; Mylonakis E
J Infect Dis; 2023 Jan; 227(2):226-235. PubMed ID: 36056913
[TBL] [Abstract][Full Text] [Related]
5. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.
Peng D; Xing HY; Li C; Wang XF; Hou M; Li B; Chen JH
BMC Gastroenterol; 2020 Oct; 20(1):348. PubMed ID: 33076834
[TBL] [Abstract][Full Text] [Related]
6. Thymosin alpha1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro.
Baumann CA; Badamchian M; Goldstein AL
Int J Immunopharmacol; 2000 Dec; 22(12):1057-66. PubMed ID: 11137612
[TBL] [Abstract][Full Text] [Related]
7. Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.
Li X; Liu L; Yang Y; Yang X; Wang C; Li Y; Ge Y; Shi Y; Lv P; Zhou H; Luo P; Huang S
Int Immunopharmacol; 2021 Jan; 90():107022. PubMed ID: 33160854
[TBL] [Abstract][Full Text] [Related]
8. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H
Front Immunol; 2021; 12():568789. PubMed ID: 34149679
[TBL] [Abstract][Full Text] [Related]
9. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection.
Minutolo A; Petrone V; Fanelli M; Maracchioni C; Giudice M; Teti E; Coppola L; Sorace C; Iannetta M; Tony Miele M; Bernardini S; Mastino A; Sinibaldi Vallebona P; Balestrieri E; Andreoni M; Sarmati L; Grelli S; Garaci E; Matteucci C
Int Immunopharmacol; 2023 May; 118():110055. PubMed ID: 36989892
[TBL] [Abstract][Full Text] [Related]
10. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.
Shang W; Zhang B; Ren Y; Wang W; Zhou D; Li Y
Int Immunopharmacol; 2023 Jan; 114():109584. PubMed ID: 36527881
[TBL] [Abstract][Full Text] [Related]
11. Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application.
Severa M; Zhang J; Giacomini E; Rizzo F; Etna MP; Cruciani M; Garaci E; Chopp M; Coccia EM
Mult Scler Relat Disord; 2019 Jan; 27():52-60. PubMed ID: 30317071
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
Liu F; Wang HM; Wang T; Zhang YM; Zhu X
BMC Infect Dis; 2016 Sep; 16():488. PubMed ID: 27633969
[TBL] [Abstract][Full Text] [Related]
13. Thymosin alpha 1 treatment for patients with sepsis.
Pei F; Guan X; Wu J
Expert Opin Biol Ther; 2018 Jul; 18(sup1):71-76. PubMed ID: 30063866
[TBL] [Abstract][Full Text] [Related]
14. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application.
Tao N; Xu X; Ying Y; Hu S; Sun Q; Lv G; Gao J
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110771
[TBL] [Abstract][Full Text] [Related]
15. Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing.
Bai H; Liang L; Qi X; Xu Y; Liu Y; Ren D; Cai Z; Mao W; Wang X; Qin H; Hu F; Shi B
Int Immunopharmacol; 2023 Nov; 124(Pt B):110983. PubMed ID: 37769533
[TBL] [Abstract][Full Text] [Related]
16. Thymalfasin for the treatment of chronic hepatitis B.
Chien RN; Liaw YF
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):9-16. PubMed ID: 15482167
[TBL] [Abstract][Full Text] [Related]
17. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.
Liu Y; Pan Y; Hu Z; Wu M; Wang C; Feng Z; Mao C; Tan Y; Liu Y; Chen L; Li M; Wang G; Yuan Z; Diao B; Wu Y; Chen Y
Clin Infect Dis; 2020 Nov; 71(16):2150-2157. PubMed ID: 32442287
[TBL] [Abstract][Full Text] [Related]
18. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.
Li C; Bo L; Liu Q; Jin F
Int J Infect Dis; 2015 Apr; 33():90-6. PubMed ID: 25532482
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections.
Bellet MM; Renga G; Pariano M; Stincardini C; D'Onofrio F; Goldstein AL; Garaci E; Romani L; Costantini C
Int Immunopharmacol; 2023 Apr; 117():109949. PubMed ID: 36881979
[TBL] [Abstract][Full Text] [Related]
20. Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases.
Pica F; Chimenti MS; Gaziano R; Buè C; Casalinuovo IA; Triggianese P; Conigliaro P; Di Carlo D; Cordero V; Adorno G; Volpi A; Perricone R; Garaci E
Clin Exp Immunol; 2016 Oct; 186(1):39-45. PubMed ID: 27350088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
